Isis Pharmaceuticals

Alnylam, Isis extend decade-long partnership for RNA therapeutics

Tuesday, January 13, 2015 09:00 AM

Isis Pharmaceuticals, based in Carlsbad, Calif., and Alnylam Pharmaceuticals, based in Cambridge, Mass., have formed a new agreement, extending their existing strategic partnership—formed originally in 2004—to lead the development and commercialization of RNA therapeutics.

More... »


Isis Pharmaceuticals, Janssen collaborate

Wednesday, January 7, 2015 12:59 PM

Isis Pharmaceuticals, based in Carlsbad, Calif., has entered into a global collaboration with Janssen Biotech to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract. The collaboration brings together Isis' RNA-targeted technology platform and the expertise of Janssen in autoimmune disorders and therapeutic formulation to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders in the GI tract.

More... »


Isis earns $5 million milestone Payment from GSK

Tuesday, November 19, 2013 12:35 PM

Isis Pharmaceuticals has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease. 

More... »

Isis earns $10 million milestone payment from Biogen Idec

Thursday, October 17, 2013 10:31 AM

Isis Pharmaceuticals has earned a $10 million milestone payment from Biogen Idec related to the selection and advancement of ISIS-DMPKRx to treat myotonic dystrophy type I (DM1).

More... »

GSK pays Isis $7 million for ISIS-GSK3Rx milestones

Tuesday, October 8, 2013 07:00 AM

GlaxoSmithKline (GSK) has added development candidate ISIS-GSK3Rx to its collaboration with Isis Pharmaceuticals. Isis earned $7 million in milestone payments associated with the advancement of this program. ISIS-GSK3Rx is an antisense drug designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3Rx to phase II proof-of-concept, after which GSK has an exclusive option to in-license the program and further develop and commercialize the asset.

More... »

Biogen Idec, Isis Pharmaceuticals collaborate on neurological disorders

Monday, September 9, 2013 12:07 PM

Biogen Idec and Isis Pharmaceuticals have entered a broad, six-year research collaboration to leverage antisense technology to advance the treatment of neurological diseases. The agreement combines Biogen Idec's experience in neurology with Isis' antisense technology to develop novel therapies to treat neurological disorders.

More... »

Roche, Isis Pharmaceuticals form alliance for Huntington's disease

Monday, April 8, 2013 02:29 PM

Basel, Switzerland-based Roche and Isis Pharmaceuticals of Carlsbad, Calif., have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology.

More... »

Isis, AstraZeneca form strategic alliance on RNA therapeutics for cancer

Wednesday, December 12, 2012 09:51 AM

Isis Pharmaceuticals of Carlsbad, Calif., and global biopharmaceutical company AstraZeneca have formed a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialize ISIS-STAT3Rx, a drug Isis is currently evaluating in an early clinical trial in patients with advanced lymphomas.

More... »

Biogen Idec, Isis collaborate on antisense programs for neurological disorders

Monday, December 10, 2012 11:54 AM

Weston, Mass.-based Biogen Idec and Isis Pharmaceuticals of Carlsbad, Calif., have entered into a global collaboration agreement to discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders. Biogen Idec and Isis are already collaborating on antisense drugs to treat spinal muscular atrophy and myotonic dystrophy type 1 under previously established collaborations.

More... »

Jeff Jonas joins Shire leadership team

Tuesday, November 20, 2012 11:51 AM

Irish specialty biopharmaceutical company Shire has appointed Jeff Jonas, MD, as president of Shire's regenerative medicine business.

More... »


CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs